Trade Mark Journal No.2026/009 27 February 2026

UK00004339401 11 February 2026 (5,42)

DREN BIO

International priority date claimed: 12 August 2025 (United States of America) (99333153)

Class 5: Pharmaceuticals; medical preparations; Pharmaceutical preparations for use in cancer, neurological disorders, allergies, infectious diseases, immunologic diseases, orphan diseases, rare diseases, and autoimmune disease treatment; pharmaceutical preparations for use in the fields of oncology, neurology, allergy, infectiology, immunology, autoimmunity, orphan diseases, rare diseases, and immunity; pharmaceutical preparations for tumor treatment; pharmaceutical preparations for suppressing tumors; pharmaceutical products for the prevention and treatment of cancer, neurological disorders, allergies, infectious diseases, immunologic diseases, orphan diseases, rare diseases, and autoimmune diseases.
Class 42: Scientific research and development; pharmaceutical research and development; research and development in the field of biotechnology; research and development of pharmaceuticals in the fields of oncology, neurology, allergy, infectiology, immunology, autoimmunity, orphan diseases, rare diseases, and immunity; research and development of pharmaceuticals for treating tumors; research and development services in the field of medical and pharmaceutical preparations; research and development of pharmaceuticals for the treatment of cancer, neurological disorders, allergies, infectious diseases, immunologic diseases, orphan diseases, rare diseases, and autoimmune diseases; pharmaceutical research in the fields of oncology, tumor suppression, neurology, allergy, infectiology, immunology, autoimmunity, orphan diseases, rare diseases, and immunity; information, consultancy and advisory services in relation to all of the above.

Dren Bio Management, Inc.

Representative: CMS Cameron McKenna Nabarro Olswang LLP